References
Key articles
McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018 Mar 19;66(7):e1-48.Full text Abstract
Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on Management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021 Jun 24:ciab549.Full text Abstract
Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev. 2017;(3):CD004610.Full text Abstract
van Prehn J, Reigadas E, Vogelzang EH, et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect. 2021 Dec;27 Suppl 2:S1-S21.Full text Abstract
Reference articles
1. Lawson PA, Citron DM, Tyrrell KL, et al. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Prévot 1938. Anaerobe. 2016 Aug;40:95-9. Abstract
2. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018 Mar 19;66(7):e1-48.Full text Abstract
3. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ. 2004 Jul 6;171(1):51-8.Full text Abstract
4. Balsells E, Shi T, Leese C, et al. Global burden of Clostridium difficile infections: a systematic review and meta-analysis. J Glob Health. 2019 Jun;9(1):010407.Full text Abstract
5. Turner NA, Grambow SC, Woods CW, et al. Epidemiologic trends in Clostridioides difficile infections in a regional community hospital network. JAMA Netw Open. 2019 Oct 2;2(10):e1914149.Full text Abstract
6. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015 Feb 26;372(9):825-34.Full text Abstract
7. Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI. BMC Infect Dis. 2021 May 19;21(1):456.Full text Abstract
8. Abrahamian FM, Talan DA, Krishnadasan A, et al; EMERGEncy ID NET Study Group. Clostridium difficile infection among US emergency department patients with diarrhea and no vomiting. Ann Emerg Med. 2017 Jul;70(1):19-27;e4. Abstract
9. Bartlett JG, Perl TM. The new Clostridium difficile - what does it mean? N Engl J Med. 2005 Dec 8;353(23):2503-5. Abstract
10. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005 Dec 8;353(23):2442-9.Full text Abstract
11. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005 Dec 8;353(23):2433-41.Full text Abstract
12. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006 Nov 21;145(10):758-64. Abstract
13. Carlson TJ, Blasingame D, Gonzales-Luna AJ, et al. Clostridioides difficile ribotype 106: a systematic review of the antimicrobial susceptibility, genetics, and clinical outcomes of this common worldwide strain. Anaerobe. 2020 Apr;62:102142. Abstract
14. Sheitoyan-Pesant C, Abou Chakra CN, Pépin J, et al. Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection. Clin Infect Dis. 2016 Mar 1;62(5):574-80.Full text Abstract
15. Ma GK, Brensinger CM, Wu Q, et al. Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: a cohort study. Ann Intern Med. 2017 Aug 1;167(3):152-8. Abstract
16. van Rossen TM, Ooijevaar RE, Vandenbroucke-Grauls CMJE, et al. Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review. Clin Microbiol Infect. 2022 Mar;28(3):321-31.Full text Abstract
17. Mehta P, Nahass RG, Brunetti L. Acid suppression medications during hospitalization as a risk factor for recurrence of clostridioides difficile Infection: systematic review and meta-analysis. Clin Infect Dis. 2021 Jul 1;73(1):e62-8.Full text Abstract
18. UK Health Security Agency. C. difficile infection: monthly data by prior trust exposure. Dec 2024 [internet publication].Full text
19. European Centre for Disease Prevention and Control. Healthcare-associated infections: Clostridium difficile infections - annual epidemiological report for 2018-2020. May 2024 [internet publication].Full text
20. Borren NZ, Ghadermarzi S, Hutfless S, et al. The emergence of Clostridium difficile infection in Asia: a systematic review and meta-analysis of incidence and impact. PLoS One. 2017 May 2;12(5):e0176797.Full text Abstract
21. Treatment of Clostridium difficile infection. Med Lett Drugs Ther. 2011 Feb 21;53(1358):14-5. Abstract
22. Schroeder MS. Clostridium difficile-associated diarrhea. Am Fam Physician. 2005 Mar 1;71(5):921-8.Full text Abstract
23. Anjewierden S, Han Z, Brown AM, et al. Risk factors for Clostridioides difficile colonization among hospitalized adults: a meta-analysis and systematic review. Infect Control Hosp Epidemiol. 2021 May;42(5):565-72. Abstract
24. Miller AC, Segre AM, Pemmaraju SV, et al. Association of household exposure to primary Clostridioides difficile infection with secondary infection in family members. JAMA Netw Open. 2020 Jun 1;3(6):e208925.Full text Abstract
25. Slimings C, Riley TV. Antibiotics and healthcare facility-associated Clostridioides difficile infection: systematic review and meta-analysis 2020 update. J Antimicrob Chemother. 2021 Jun 18;76(7):1676-88.Full text Abstract
26. Teng C, Reveles KR, Obodozie-Ofoegbu OO, et al. Clostridium difficile infection risk with important antibiotic classes: an analysis of the FDA Adverse Event Reporting System. Int J Med Sci. 2019 May 7;16(5):630-5.Full text Abstract
27. Tariq R, Cho J, Kapoor S, et al. Low risk of primary Clostridium difficile infection with tetracyclines: a systematic review and metaanalysis. Clin Infect Dis. 2018 Feb 1;66(4):514-22.Full text Abstract
28. Dingle KE, Didelot X, Quan TP, et al. Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infect Dis. 2017 Apr;17(4):411-21.Full text Abstract
29. Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017 Sep;17(9):990-1001. Abstract
30. Blumenthal KG, Lu N, Zhang Y, et al. Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study. BMJ. 2018 Jun 27;361:k2400.Full text Abstract
31. Blixt T, Gradel KO, Homann C, et al. Asymptomatic carriers contribute to nosocomial Clostridium difficile infection: a cohort study of 4508 patients. Gastroenterology. 2017 Apr;152(5):1031-41;e2. Abstract
32. Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003 Jul;54(3):243-5. Abstract
33. US Food and Drug Administration. FDA drug safety communication: Clostridium difficile associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Feb 2012 [internet publication].Full text
34. Arriola V, Tischendorf J, Musuuza J, et al. Assessing the risk of hospital-acquired clostridium difficile infection with proton pump inhibitor use: a meta-analysis. Infect Control Hosp Epidemiol. 2016 Dec;37(12):1408-17.Full text Abstract
35. Oshima T, Wu L, Li M, et al. Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis. J Gastroenterol. 2018 Jan;53(1):84-94. Abstract
36. Cao F, Chen CX, Wang M, et al. Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection. J Hosp Infect. 2018 Jan;98(1):4-13. Abstract
37. Ben-Eltriki M, Chhabra M, Cassels A, et al. Inappropriate use of proton pump inhibitor among elderly patients in British Columbia: what are the long-term adverse events? Curr Drug Saf. 2024;19(2):244-7.Full text Abstract
38. Azab M, Doo L, Doo DH, et al. Comparison of the hospital-acquired Clostridium difficile infection risk of using proton pump inhibitors versus histamine-2 receptor antagonists for prophylaxis and treatment of stress ulcers: a systematic review and meta-analysis. Gut Liver. 2017 Nov 15;11(6):781-8.Full text Abstract
39. Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008 Jun;103(6):1443-50. Abstract
40. Razik R, Rumman A, Bahreini Z, et al. Recurrence of Clostridium difficile infection in ptients with inflammatory bowel disease: the RECIDIVISM study. Am J Gastroenterol. 2016 Aug;111(8):1141-6. Abstract
41. Tariq R, Law CCY, Khanna S, et al. The impact of Clostridium difficile infection on mortality in patients with inflammatory bowel disease: a systematic review and meta-analysis. J Clin Gastroenterol. 2019 Feb;53(2):127-33. Abstract
42. Balram B, Battat R, Al-Khoury A, et al. Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2019 Jan 1;13(1):27-38.Full text Abstract
43. Donnelly JP, Wang HE, Locke JE, et al. Hospital-onset Clostridium difficile infection among solid organ transplant recipients. Am J Transplant. 2015 Nov;15(11):2970-7.Full text Abstract
44. Paudel S, Zacharioudakis IM, Zervou FN, et al. Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies. PLoS One. 2015 Apr 17;10(4):e0124483.Full text Abstract
45. Zacharioudakis IM, Ziakas PD, Mylonakis E. Clostridium difficile infection in the hematopoietic unit: a meta-analysis of published studies. Biol Blood Marrow Transplant. 2014 Oct;20(10):1650-4.Full text Abstract
46. Luo Y, Zhang S, Shang H, et al. Prevalence of Clostridium difficile infection in the hematopoietic transplantation setting: update of systematic review and meta-analysis. Front Cell Infect Microbiol. 2022;12:801475.Full text Abstract
47. Phatharacharukul P, Thongprayoon C, Cheungpasitporn W, et al. The risks of incident and recurrent Clostridium difficile-associated diarrhea in chronic kidney disease and end-stage kidney disease patients: a systematic review and meta-analysis. Dig Dis Sci. 2015 Oct;60(10):2913-22. Abstract
48. Sanchez TH, Brooks JT, Sullivan PS, et al; Adult/Adolescent Spectrum of HIV Disease Study Group. Bacterial diarrhea in persons with HIV infection, United States, 1992-2002. Clin Infect Dis. 2005 Dec 1;41(11):1621-7.Full text Abstract
49. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis. 1993 Jul;17(1):109-13. Abstract
50. Li Y, Cai H, Sussman DA, et al. Association between immunosuppressive therapy and outcome of Clostridioides difficile infection: systematic review and meta-analysis. Dig Dis Sci. 2022 Aug;67(8):3890-903. Abstract
51. Southern WN, Rahmani R, Aroniadis O, et al. Postoperative Clostridium difficile-associated diarrhea. Surgery. 2010 Jul;148(1):24-30.Full text Abstract
52. Khorasani S, Dossa F, McKechnie T, et al. Association between preoperative oral antibiotics and the incidence of postoperative Clostridium difficile infection in adults undergoing elective colorectal resection: a systematic review and meta-analysis. Dis Colon Rectum. 2020 Apr;63(4):545-61. Abstract
53. Harries RL, Ansell J, Codd RJ, et al. A systematic review of Clostridium difficile infection following reversal of ileostomy. Colorectal Dis. 2017 Oct;19(10):881-7. Abstract
54. Tirelli F, Langellotti L, Lorenzon L, et al. Clostridium difficile infection after stoma reversal surgery: a systematic review and meta-analysis of the literature. Int J Colorectal Dis. 2024 May 29;39(1):81.Full text Abstract
55. Furuya-Kanamori L, Wangdi K, Yakob L, et al. 25-hydroxyvitamin D concentrations and Clostridium difficile infection: a meta-analysis. JPEN J Parenter Enteral Nutr. 2017 Jul;41(5):890-5. Abstract
56. Borji S, Kadivarian S, Dashtbin S, et al. Global prevalence of Clostridioides difficile in 17,148 food samples from 2009 to 2019: a systematic review and meta-analysis. J Health Popul Nutr. 2023 Apr 18;42(1):36.Full text Abstract
57. Su GL, Ko CW, Bercik P, et al. AGA Clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. Gastroenterology. 2020 Aug;159(2):697-705. Abstract
58. Kelly CR, Fischer M, Allegretti JR, et al. ACG Clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol. 2021 Jun 1;116(6):1124-47.Full text Abstract
59. McFarland LV, Kullar R, Johnson S, et al. Why do ACG and AGA guidelines differ for the use of probiotics and the prevention of CDI? Am J Gastroenterol. 2022 Mar 1;117(3):501. Abstract
60. Goldenberg JZ, Yap C, Lytvyn L, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017 Dec 19;12:CD006095.Full text Abstract
61. Shen NT, Maw A, Tmanova LL, et al. Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterology. 2017 Jun;152(8):1889-900;e9.Full text Abstract
62. Ma Y, Yang JY, Peng X, et al. Which probiotic has the best effect on preventing Clostridium difficile-associated diarrhea? A systematic review and network meta-analysis. J Dig Dis. 2020 Feb;21(2):69-80. Abstract
63. Deschênes P, Chano F, Dionne LL, et al. Efficacy of the World Health Organization-recommended handwashing technique and a modified washing technique to remove Clostridium difficile from hands. Am J Infect Control. 2017 Aug 1;45(8):844-8. Abstract
64. Banach DB, Bearman G, Barnden M, et al. Duration of contact precautions for acute-care settings. Infect Control Hosp Epidemiol. 2018 Feb;39(2):127-44.Full text Abstract
65. Rutala WA, Weber DJ. Sterilization, high-level disinfection, and environmental cleaning. Infect Dis Clin North Am. 2011 Mar;25(1):45-76. Abstract
66. National Institute for Health and Care Excellence. Infection prevention and control. Apr 2014 [internet publication].Full text
67. Kato H, Hagihara M, Asai N, et al. A systematic review and meta-analysis of decontamination methods to prevent hospital environmental contamination and transmission of Clostridioidesdifficile. Anaerobe. 2022 Feb;73:102478. Abstract
68. Lewis SR, Schofield-Robinson OJ, Rhodes S, et al. Chlorhexidine bathing of the critically ill for the prevention of hospital-acquired infection. Cochrane Database Syst Rev. 2019 Aug 30;8(8):CD012248.Full text Abstract
69. Alshrari AS, Hudu SA, Elmigdadi F, et al. The urgent threat of Clostridioides difficile infection: a glimpse of the drugs of the future, with related patents and prospects. Biomedicines. 2023 Feb 1;11(2):426.Full text Abstract
70. Tschudin-Sutter S, Kuijper EJ, Durovic A, et al. Guidance document for prevention of Clostridium difficile infection in acute healthcare settings. Clin Microbiol Infect. 2018 Oct;24(10):1051-4.Full text Abstract
71. Centers for Disease Control and Prevention. C. diff (Clostridioides difficile): clinical testing and diagnosis for CDI. Mar 2024 [internet publication].Full text
72. Arimoto J, Horita N, Kato S, et al. Diagnostic test accuracy of glutamate dehydrogenase for Clostridium difficile: systematic review and meta-analysis. Sci Rep. 2016 Jul 15;6:29754.Full text Abstract
73. Deshpande A, Pasupuleti V, Pant C, et al. Potential value of repeat stool testing for Clostridium difficile stool toxin using enzyme immunoassay? Curr Med Res Opin. 2010 Nov;26(11):2635-41. Abstract
74. Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on Management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021 Jun 24:ciab549.Full text Abstract
75. Zhang VRY, Woo ASJ, Scaduto C, et al. Systematic review on the definition and predictors of severe Clostridiodes difficile infection. J Gastroenterol Hepatol. 2021 Jan;36(1):89-104.Full text Abstract
76. Infectious Diseases Society of America. Guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2024 update by IDSA/ASM. Mar 2024 [internet publication].Full text
77. Angarone M, Snydman DR; AST ID Community of Practice. Diagnosis and management of diarrhea in solid-organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019 Sep;33(9):e13550. Abstract
78. Sartelli M, Di Bella S, McFarland LV, et al. 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World J Emerg Surg. 2019 Feb 28;14:8.Full text Abstract
79. Bishop EJ, Tiruvoipati R. Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines. J Antimicrob Chemother. 2022 Dec 23;78(1):21-30.Full text Abstract
80. Peery AF, Kelly CR, Kao D, et al. AGA clinical practice guideline on fecal microbiota-based therapies for select gastrointestinal diseases. Gastroenterology. 2024 Mar;166(3):409-34.Full text Abstract
81. Beinortas T, Burr NE, Wilcox MH, et al. Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis. Lancet Infect Dis. 2018 Sep;18(9):1035-44. Abstract
82. Okumura H, Fukushima A, Taieb V, et al. Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: a network meta-analysis. J Infect Chemother. 2020 Jan;26(1):43-50.Full text Abstract
83. Tashiro S, Mihara T, Sasaki M, et al. Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: a systematic review and meta-analysis of randomized controlled trials. J Infect Chemother. 2022 Nov;28(11):1536-45. Abstract
84. Liao JX, Appaneal HJ, Vicent ML, et al. Path of least recurrence: a systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection. Pharmacotherapy. 2022 Nov;42(11):810-27. Abstract
85. Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev. 2017;(3):CD004610.Full text Abstract
86. Khanna S, Shin A, Kelly CP. Management of Clostridium difficile infection in inflammatory bowel disease: expert review from the Clinical Practice Updates Committee of the AGA Institute. Clin Gastroenterol Hepatol. 2017 Feb;15(2):166-74.Full text Abstract
87. D'Aoust J, Battat R, Bessissow T. Management of inflammatory bowel disease with Clostridium difficile infection. World J Gastroenterol. 2017 Jul 21;23(27):4986-5003.Full text Abstract
88. Cimolai N. Does oral vancomycin use necessitate therapeutic drug monitoring? Infection. 2020 Apr;48(2):173-82. Abstract
89. Sholeh M, Krutova M, Forouzesh M, et al. Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2020 Sep 25;9(1):158.Full text Abstract
90. Ng QX, Loke W, Foo NX, et al A systematic review of the use of rifaximin for Clostridium difficile infections. Anaerobe. 2019 Feb;55:35-9. Abstract
91. Kechagias KS, Chorepsima S, Triarides NA, et al. Tigecycline for the treatment of patients with Clostridium difficile infection: an update of the clinical evidence. Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1053-8. Abstract
92. Jaber MR, Olafsson S, Fung WL, et al. Clinical review of the management of fulminant Clostridium difficile infection. Am J Gastroenterol. 2008 Dec;103(12):3195-203;quiz 3204. Abstract
93. Forrester JD, Colling KP, Diaz JJ, et al. Surgical Infection Society guidelines for total abdominal colectomy versus diverting loop ileostomy with antegrade intra-colonic lavage for the surgical management of severe or fulminant, non-perforated Clostridioides difficile Colitis. Surg Infect (Larchmt). 2022 Mar;23(2):97-104. Abstract
94. Felsenreich DM, Gachabayov M, Rojas A, et al. Meta-analysis of postoperative mortality and morbidity after total abdominal colectomy versus loop ileostomy with colonic lavage for fulminant Clostridium difficile colitis. Dis Colon Rectum. 2020 Sep;63(9):1317-26. Abstract
95. McKechnie T, Lee Y, Springer JE, et al. Diverting loop ileostomy with colonic lavage as an alternative to colectomy for fulminant Clostridioides difficile: a systematic review and meta-analysis. Int J Colorectal Dis. 2020 Jan;35(1):1-8. Abstract
96. Singh T, Bedi P, Bumrah K, et al. Fecal microbiota transplantation and medical therapy for Clostridium difficile infection : meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2022 Nov-Dec 01;56(10):881-8. Abstract
97. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011 Feb 3;364(5):422-31.Full text Abstract
98. Stevens VW, Nelson RE, Schwab-Daugherty EM, et al. Comparative effectiveness of vancomycin and metronidazole for the prevention of recurrence and death in patients with Clostridium difficile infection. JAMA Intern Med. 2017 Apr 1;177(4):546-53. Abstract
99. Sehgal K, Zandvakili I, Tariq R, et al. Systematic review and meta-analysis: efficacy of vancomycin taper and pulse regimens in Clostridioides difficile infection. Expert Rev Anti Infect Ther. 2022 Apr;20(4):577-83. Abstract
100. Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017 Jan 26;376(4):305-17.Full text Abstract
101. Mohamed MFH, Ward C, Beran A, et al. Efficacy, safety, and cost-effectiveness of bezlotoxumab in preventing recurrent Clostridioides difficile infection : systematic review and meta-analysis. J Clin Gastroenterol. 2024 Apr 1;58(4):389-401. Abstract
102. Alhifany AA, Almutairi AR, Almangour TA, et al. Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent Clostridium difficile infections: a systematic review and Bayesian network meta-analysis of randomised controlled trials. BMJ Open. 2019 Nov 7;9(11):e031145.Full text Abstract
103. Minkoff NZ, Aslam S, Medina M, et al. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile). Cochrane Database Syst Rev. 2023 Apr 25;4(4):CD013871.Full text Abstract
104. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013 Jan 31;368(5):407-15.Full text Abstract
105. Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016 Jan 12;315(2):142-9.Full text Abstract
106. Hota SS, Sales V, Tomlinson G, et al. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent Clostridium difficile infection: an open-label, randomized controlled trial. Clin Infect Dis. 2017 Feb 1;64(3):265-71.Full text Abstract
107. Lai CY, Sung J, Cheng F, et al. Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation. Aliment Pharmacol Ther. 2019 Feb;49(4):354-63. Abstract
108. Du C, Luo Y, Walsh S, et al. Oral fecal microbiota transplant capsules are safe and effective for recurrent Clostridioides difficile infection: a systematic review and meta-analysis. J Clin Gastroenterol. 2021 Apr 1;55(4):300-8. Abstract
109. Kelly CR, Yen EF, Grinspan AM, et al. Fecal microbiota transplantation Is highly effective in real-world practice: initial results from the FMT National Registry. Gastroenterology. 2021 Jan; 160(1):183-92.e3.Full text Abstract
110. Tariq R, Pardi DS, Bartlett MG, et al. Low cure rates in controlled trials of fecal microbiota transplantation for recurrent Clostridium difficile infection: A Systematic Review and Meta-analysis. Clin Infect Dis. 2019 Apr 8;68(8):1351-8.Full text Abstract
111. Rokkas T, Gisbert JP, Gasbarrini A, et al. A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Clostridium difficile infection. United European Gastroenterol J. 2019 Oct;7(8):1051-63.Full text Abstract
112. Hui W, Li T, Liu W, et al. Fecal microbiota transplantation for treatment of recurrent C. difficile infection: an updated randomized controlled trial meta-analysis. PLoS One. 2019 Jan 23;14(1):e0210016.Full text Abstract
113. Baunwall SMD, Andreasen SE, Hansen MM, et al. Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2022 Sep 21:S2468-1253(22)00276-X. Abstract
114. Moayyedi P, Yuan Y, Baharith H, et al. Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea: a systematic review of randomised controlled trials. Med J Aust. 2017 Aug 21;207(4):166-72.Full text Abstract
115. Hvas CL, Dahl Jørgensen SM, Jørgensen SP, et al. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology. 2019 Apr;156(5):1324-32.e3. Abstract
116. Beran A, Sharma S, Ghazaleh S, et al. Predictors of fecal microbiota transplant failure in Clostridioides difficile infection : an updated meta-analysis. J Clin Gastroenterol. 2023 Apr 1;57(4):389-99. Abstract
117. Ramai D, Zakhia K, Fields PJ, et al. Fecal microbiota transplantation (FMT) with colonoscopy is superior to enema and nasogastric tube while comparable to capsule for the treatment of recurrent Clostridioides difficile infection: a systematic review and meta-analysis. Dig Dis Sci. 2021 Feb;66(2):369-80. Abstract
118. Tang G, Yin W, Liu W. Is frozen fecal microbiota transplantation as effective as fresh fecal microbiota transplantation in patients with recurrent or refractory Clostridium difficile infection: a meta-analysis? Diagn Microbiol Infect Dis. 2017 Aug;88(4):322-9. Abstract
119. Furuya-Kanamori L, Doi SA, Paterson DL, et al. Upper versus lower gastrointestinal delivery for transplantation of fecal microbiota in recurrent or refractory Clostridium difficile infection: a collaborative analysis of individual patient data from 14 studies. J Clin Gastroenterol. 2017 Feb;51(2):145-50. Abstract
120. Gangwani MK, Aziz M, Aziz A, et al. Fresh versus frozen versus lyophilized fecal microbiota transplant for recurrent Clostridium difficile infection: a systematic review and network meta-analysis. J Clin Gastroenterol. 2023 Mar 1;57(3):239-45. Abstract
121. Wang S, Xu M, Wang W, et al. Systematic review: adverse events of fecal microbiota transplantation. PLoS One. 2016 Aug 16;11(8):e0161174.Full text Abstract
122. Marcella C, Cui B, Kelly CR, et al. Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020. Aliment Pharmacol Ther. 2021 Jan;53(1):33-42. Abstract
123. Pomares Bascuñana RÁ, Veses V, Sheth CC. Effectiveness of fecal microbiota transplant for the treatment of Clostridioides difficile diarrhea: a systematic review and meta-analysis. Lett Appl Microbiol. 2021 Aug;73(2):149-58.Full text Abstract
124. Khoruts A, Rank KM, Newman KM, et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2016 Oct; 14(10):1433-8.Full text Abstract
125. Chen T, Zhou Q, Zhang D, et al. Effect of faecal microbiota transplantation for treatment of Clostridium difficile infection in patients with inflammatory bowel disease: a systematic review and meta-analysis of cohort studies. J Crohns Colitis. 2018 May 25;12(6):710-7.Full text Abstract
126. Tariq R, Syed T, Yadav D, et al. Outcomes of fecal microbiota transplantation for C. difficile infection in inflammatory bowel disease : a systematic review and meta-analysis. J Clin Gastroenterol. 2023 Mar 1;57(3):285-93. Abstract
127. Shogbesan O, Poudel DR, Victor S, et al. A systematic review of the efficacy and safety of fecal microbiota transplant for Clostridium difficile infection in immunocompromised patients. Can J Gastroenterol Hepatol. 2018 Sep 2;2018:1394379.Full text Abstract
128. US Food and Drug Administration. Important safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse reactions due to transmission of multi-drug resistant organisms. Jun 2019 [internet publication].Full text
129. US Food and Drug Administration. Fecal microbiota for transplantation: safety alert - risk of serious adverse events likely due to transmission of pathogenic organisms. Apr 2020 [internet publication].Full text
130. US Food and Drug Administration. Safety alert regarding use of fecal microbiota for transplantation and additional safety protections pertaining to monkeypox virus. Aug 2022 [internet publication].Full text
131. U.S. Food and Drug Administration. Safety alert regarding use of fecal microbiota for transplantation and additional safety protections pertaining to SARS-CoV-2 and COVID-19. Mar 2020 [internet publication].Full text
132. Ianiro G, Murri R, Sciumè GD, et al. Incidence of bloodstream infections, length of hospital stay, and survival in patients with recurrent Clostridioides difficile infection treated with fecal microbiota transplantation or antibiotics: a prospective cohort study. Ann Intern Med. 2019 Nov 19;171(10):695-702. Abstract
133. Bafeta A, Yavchitz A, Riveros C, et al. Methods and reporting studies assessing fecal microbiota transplantation: a systematic review. Ann Intern Med. 2017 Jul 4;167(1):34-9. Abstract
134. Monday L, Tillotson G, Chopra T. Microbiota-based live biotherapeutic products for Clostridioides difficile infection- the devil is in the details. Infect Drug Resist. 2024 Feb 15:17:623-39.Full text Abstract
135. Lavoie T, Appaneal HJ, LaPlante KL. Advancements in novel live biotherapeutic products for Clostridioides difficile infection prevention. Clin Infect Dis. 2023 Dec 5;77(suppl 6):S447-54.Full text Abstract
136. Khanna S, Assi M, Lee C, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs. 2022 Oct;82(15):1527-38.Full text Abstract
137. Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med. 2022 Jan 20;386(3):220-9.Full text Abstract
138. Louie T, Golan Y, Khanna S, et al. VE303, a defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: a randomized clinical trial. JAMA. 2023 Apr 25;329(16):1356-66. Abstract
139. ClinicalTrials.gov. Exploratory study to assess delivery of LMN-201 components via enteric capsules in the gut of individuals with ostomies. ClinicalTrials.gov identifier: NCT04893239. Mar 2022 [internet publication].Full text
140. ClinicalTrials.gov. LMN-201 for prevention of C. difficile infection recurrence. ClinicalTrials.gov identifier: NCT05330182. Nov 2022 [internet publication].Full text
141. Vickers RJ, Tillotson GS, Nathan R, et al. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study. Lancet Infect Dis. 2017 Jul;17(7):735-44.Full text Abstract
142. Kokai-Kun JF, Roberts T, Coughlin O, et al. Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial. Lancet Infect Dis. 2019 May;19(5):487-96. Abstract
143. McCoy RM, Klick A, Hill S, et al. Luminal toxin-binding agents for Clostridium difficile infection. J Pharm Pract. 2016 Aug;29(4):361-7. Abstract
144. Centers for Disease Control and Prevenion. C. diff (Clostridioides difficile): clinical guidance for C. diff prevention in acute care facilities. Mar 2024 [internet publication].Full text
145. Patel P, Robinson PD, Fisher BT, et al. Guideline for the management of Clostridioides difficile infection in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2024 update. EClinicalMedicine. 2024 Jun;72:102604.Full text Abstract
146. Kociolek LK, Gerding DN, Carrico R, et al. Strategies to prevent Clostridioides difficile infections in acute-care hospitals: 2022 update. Infect Control Hosp Epidemiol. 2023 Apr;44(4):527-49.Full text Abstract
147. Alonso CD, Maron G, Kamboj M, et al. American Society for Transplantation and Cellular Therapy series: #5-management of Clostridioides difficile infection in hematopoietic cell transplant recipients. Transplant Cell Ther. 2022 May;28(5):225-32.Full text Abstract
148. Poylin V, Hawkins AT, Bhama AR, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of Clostridioides difficile infection. Dis Colon Rectum. 2021 Jun 1;64(6):650-68.Full text Abstract
149. Mullane KM, Dubberke ER; AST ID Community of Practice. Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: Guidelines from the American Society of Transplantation Community of Practice. Clin Transplant. 2019 Sep;33(9):e13564. Abstract
150. van Prehn J, Reigadas E, Vogelzang EH, et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect. 2021 Dec;27 Suppl 2:S1-S21.Full text Abstract
151. National Institute for Health and Care Excellence. Clostridioides difficile infection: antimicrobial prescribing NICE guideline [NG199]. 23 Jul 2021 [internet publication].Full text
152. Saha S, Sehgal K, Singh S, et al. Postinfection irritable bowel syndrome following Clostridioides difficile infection: a systematic-review and meta-analysis. J Clin Gastroenterol. 2022 Feb 1;56(2):e84-93. Abstract
153. Almroth S, Mohale M, Latham MC. Grandma ahead of her time: traditional ways of diarrhoea management in Lesotho. J Diarrhoeal Dis Res. 1997 Sep;15(3):167-72. Abstract
154. Brown CC, Manis MM, Bohm NM, et al. Oral vancomycin for secondary prophylaxis of Clostridium difficile infection. Ann Pharmacother. 2019 Apr;53(4):396-401. Abstract
Use of this content is subject to our disclaimer